Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)

Ähnliche Einträge

• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  von: Carel W. le Roux, et al.
  Veröffentlicht: (2024)
• Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial
  von: Koutaro Yokote, et al.
  Veröffentlicht: (2026)
• Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
  von: Carel W. le Roux, et al.
  Veröffentlicht: (2025)
• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  von: Faisal I. Almohaileb, et al.
  Veröffentlicht: (2025)
• Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
  von: Martin T. W. Kueh, et al.
  Veröffentlicht: (2024)